Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
ViroLogic and ACLARA Announce Stockholder Approval of Merger Merger Expected to Be Completed By End of Day SOUTH SAN FRANCISCO, Calif. and MOUNTAIN VIEW, Calif., Dec. 10 /PRNewswire-FirstCall/...
Iceland Genomics Corporation and ACLARA Collaborating on Cancer Biomarkers REYKJAVIK, Iceland, Dec. 2 /PRNewswire/ -- Iceland Genomics Corporation (IGC) announced today that they have entered...
ACLARA Announces Third Quarter 2004 Financial Results MOUNTAIN VIEW, Calif. Nov. 9 /PRNewswire-FirstCall/ -- ACLARA BioSciences (NASDAQ:ACLA), today reported financial results for the three and...
ViroLogic and ACLARA to Mail Revised Definitive Proxy for Proposed Merger New Date Set for Stockholder Meetings SOUTH SAN FRANCISCO, Calif. and MOUNTAIN VIEW, Calif., Nov. 8...
Clinical Data Presented at ESMO Shows ETAG(TM) System's Potential in Predicting Response to Cancer Treatment MOUNTAIN VIEW, Calif., Nov. 4 /PRNewswire-FirstCall/ -- ACLARA...
Manuel Hidalgo, M.D., Ph.D., Joins ACLARA BioSciences Scientific Advisory Board Another Distinguished Oncologist Highlights Company's Advancements in Protein-Based Diagnostics MOUNTAIN VIEW...
ViroLogic and ACLARA BioSciences Revise Merger Terms ViroLogic Provides Preliminary Third Quarter Revenue Estimate SOUTH SAN FRANCISCO, Calif. and MOUNTAIN VIEW, Calif., Oct. 19...
ACLARA and GlaxoSmithKline Evaluating eTag(TM) Technology for Patient Selection for Targeted Cancer Therapies MOUNTAIN VIEW, Calif., Oct. 5 /PRNewswire-FirstCall/ -- ACLARA...
ACLARA Data at EORTC-NCI-AACR Symposium Demonstrates ETAG(TM) System Potential in Cancer Drug Development and Treatment Prognosis MOUNTAIN VIEW, Calif. and GENEVA, Sept. 30...
ViroLogic and ACLARA Mail Definitive Proxy for Proposed Merger Date Set for Stockholder Meetings SOUTH SAN FRANCISCO, Calif. and MOUNTAIN VIEW, Calif., Sept. 28 /PRNewswire-FirstCall/...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
